An antibody treatment developed by pharmaceutical giant AstraZeneca has shown new data to show its ability to prevent and treat Covid-19.
AstraZeneca filed with the US Food and Drug Administration (FDA) last week for approval of AZD7442, which consists of two antibodies, as a preventive emergency treatment.
In new data released Monday morning from its tackle study, AstraZeneca showed that AZD7442 was effective in preventing severe illness in non-hospitalized patients with mild to moderate coronavirus when compared to a placebo.
Most of the 903 people in the study were at high risk of progression to severe Covid-19, including those with multiple health conditions.
The study found that a single 600 mg dose of AZD7442 given by injection into the muscle reduced the risk of severe Covid-19 disease or death from any cause by 50% compared to placebo in patients who were seven years old Years were symptomatic for days or less.
For those who received treatment within five days of their symptoms first appearing, AZD7442 reduced the risk of developing severe Covid or death by 67% compared to a placebo.
Hugh Montgomery, Professor of Intensive Care Medicine at University College London and lead researcher on the study, said: “With the ongoing cases of severe Covid-19 infections around the world, there is a significant need for new therapies such as AZD7442 that can be used to treat those at risk Protecting population groups from infection with Covid-19 and can also help prevent the progression to a serious illness.
“These positive results indicate that a convenient intramuscular dose of AZD7442 could play an important role in combating this devastating pandemic.”
Mene Pangalos, Executive Vice President, Biopharmaceutical Research and Development at AstraZeneca, said, “These important results for AZD7442, our long-acting antibody combination, complement the growing evidence for the use of this therapy in both the prevention and treatment of Covid-19.
“Early intervention with our antibody can significantly reduce the progression of a serious illness, with sustained protection for more than six months.”
The treatment has been billed as suitable for those who cannot be vaccinated regularly, who respond poorly to Covid-19 vaccines or whose state of health puts them at particular risk of serious illness,
The full results of the tackle study will be submitted for publication in a peer-reviewed medical journal.
A separate treatment study (Provent) published in August showed that there were no cases of serious deaths related to Covid or coronavirus in those treated with AZD7442.
The study of more than 5,000 adults found that AZD7442 reduced the risk of developing symptomatic Covid-19 by 77% compared to a placebo.
More than 75% of people in this study had health problems that put them at increased risk of serious illness or had a decreased immune response to the vaccine.
You can find more stories from where you live at Near you